From The Synchrotron To The Clinic: Translation Of A Novel Functional Lung Imaging Technology
Funder
National Health and Medical Research Council
Funding Amount
$891,834.00
Summary
Our team has recently developed a synchrotron technology with a startling capacity for dynamic functional imaging that can act as a sensitive regional indicator of lung disease. We will demonstrate that this technology can be translated from the synchrotron to the lab and eventually the clinic. We will provide proof of this concept by the application of this technology to emphysema, asthma, lung cancer, cystic fibrosis lung disease and neonatal resuscitation.
Respiratory failure at birth is a major cause of death and disease in newborn infants. At birth the airways must be cleared of liquid to allow the inhalation of air, but, little is known about the process of lung aeration, because it has not been possible to observe or measure it. We have developed imaging and analytical techniques to observed and measure lung aeration. We will determine ventilation procedures that promote uniform lung aeration and minimise lung injury in ventilated infants.
Asthma is a National Health Priority in Australia. This project follows the major international study of asthma and allergic diseases in adults. We will re-examine people who have taken part in previous studies in Melbourne. The project also surveys people of the same age currently living in the same area. Participants complete a short postal questionnaire. In the follow-up group, responders complete a more extensive questionnaire and come to our laboratory for clinical assessments.
Revolutionising The Diagnosis And Monitoring Of CF Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$818,391.00
Summary
Cystic fibrosis (CF) lung disease starts early in childhood and relentlessly progresses, with early death a common outcome. There is currently no method capable of detecting very early disease onset nor directly assessing the effectiveness of putative treatments. This project will apply our globally unique X-ray imaging tools, which are capable of imaging lung function at any point across the entire lung, for the very early detection of CF and assessment of clinically applicable treatments.
A Randomised Controlled Trial Of Interventional Versus Conservative Treatment Of Primary Spontaneous Pneumothorax
Funder
National Health and Medical Research Council
Funding Amount
$412,315.00
Summary
Primary spontaneous pneumothorax (PSP) is a collapsed lung that occurs in otherwise healthy people without underlying lung disease. Current standard treatment is to insert a chest drain into the chest to remove the air around the collapsed lung so that the lung re-inflates rapidly ("interventional treatment"). We will determine whether doing nothing, i.e. letting the lung re-inflate slowly on its own over several weeks ("conservative treatment"), is just as good or even better for patients.
Targeting Oxidant-dependent Pathways To Improve Stroke Outcomes In COPD
Funder
National Health and Medical Research Council
Funding Amount
$1,069,574.00
Summary
Chronic Obstructive Pulmonary Disease (COPD) is a major incurable global health burden and is the 4th largest cause of death worldwide. Patients with COPD are at increased risk for stroke and this is even higher in the weeks following a lung viral infection. The reason for this is unknown so the aim of this study is to determine why people with COPD are at increased risk for stroke and then develop novel treatments to prevent or reduce stroke in COPD patients.
Determining The Role Of Vitamin D In The Development Of Asthma And Allergic Diseases In High Risk Families
Funder
National Health and Medical Research Council
Funding Amount
$351,127.00
Summary
Allergic diseases like asthma, eczema and hay-fever, prevent our children from getting a healthy start to life, and we don’t know how to prevent these conditions. Vitamin D levels may be critical in the development of childhood asthma and allergies, and they can be easily modified! Using a group of 620 children who we have followed for 20 years, we will identify the role of vitamin D levels in the development of allergic conditions, and factors that modify these relationships.
The Predictors Of Asthma And Lung Function Deficits In The Third Decade: Longitudinal Study Of MACS Sibships
Funder
National Health and Medical Research Council
Funding Amount
$1,176,908.00
Summary
This will be the world’s first birth cohort study to use substantial prospective data to investigate how biological, psychosocial, and environmental markers from birth will predict asthma and lung function in the third decade of life. Our findings will be crucial to the development of new policy and practice for the prevention and management of these conditions and uncover crucial risk factors for young adult asthma.
What Are The Lifetime Clinical Predictors And Risk Factors For Multiple Phenotypes Of Adult Asthma, COPD And Sleep Disordered Breathing? Following Up The TAHS Cohort From 1st To 6th Decade
Funder
National Health and Medical Research Council
Funding Amount
$1,950,689.00
Summary
Breathing gets impaired and impact on the productivity and quality of life when chronic respiratory diseases rise with ageing. Adult chronic respiratory diseases are major causes of illness and death but there are still many gaps in knowledge on how best to prevent and manage these diseases. The proposed program will provide evidence to guide health policy and clinical management of these diseases. These original findings will be of great importance both nationally and internationally.
Novel Methods For Promoting Organ Development And Growth
Funder
National Health and Medical Research Council
Funding Amount
$390,203.00
Summary
A revolutionary new therapy for treatment of growth restricted fetuses and premature babies is being developed through the administration of Colony Stimulating Factor (CSF-1). We have evidence that CSF-1 therapy can promote kidneys and lungs to continue development and maturation after birth. This exciting new finding allows for the application of CSF-1 therapy for both the treatment of premature babies and unborn babies with kidney defects.